After Falling 18% in 1 Day, Is This Growth Stock Done For?
With its shares plummeting 18% on March 30 and 40% over the past month, it shouldn't be too surprising to hear that investors are skeptical about the future of Avidity Biosciences (NASDAQ: RNA).
But biotechs don't behave like typical growth stocks, and they can have more staying power than what their stock prices might suggest. Let's analyze why the market dumped Avidity and whether people who invest in it now could profit down the line.
Understanding why Avidity's stock tanked requires a quick trip down memory lane to late last year.
Source Fool.com
